Kineta To Present New Preclinical Data On Its Anti-VISTA Antibody KVA12123 In Acute Myeloid Leukemia At The AACR Blood Cancer Discovery Symposium
Portfolio Pulse from Benzinga Newsdesk
Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company, announced it will present new preclinical data on its anti-VISTA antibody, KVA12123, for treating acute myeloid leukemia (AML) at the AACR Blood Cancer Discovery Symposium in Boston. The presentation by Chief Scientific Officer Thierry Guillaudeux will detail KVA12123 as a potential new immuno-oncology therapeutic target for AML. The abstract will be available in an AACR journal and the poster on Kineta's website post-conference.
February 22, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kineta, Inc. is set to present promising preclinical data on KVA12123, its anti-VISTA antibody for AML, at the AACR Symposium, potentially impacting its stock positively.
The presentation of new preclinical data on KVA12123 represents a significant milestone for Kineta, Inc., potentially enhancing its reputation in the oncology field. Positive data could lead to increased investor confidence and a positive short-term impact on KA's stock price, given the high relevance and importance of innovative cancer treatments in the biotech industry.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100